AAV review and single-cell tracking
- A Viruses review summarised clinical successes and scaling challenges for AAV-based gene therapies. - A separate BioTech MDPI piece explored real-time flow cytometry for single-cell bioprocess tracking in bioreactors. - Both items highlight growing emphasis on analytics and single-cell monitoring to support scale-up and sensitivity in vector manufacturing ( ).
Adeno-associated virus, or AAV, is a stripped-down virus used as a delivery truck for replacement genes, and researchers are now focusing as much on how to measure each batch as on the therapy itself. (mdpi.com) A February 2025 review in *Viruses* said AAV vectors have already reached the clinic in products including Luxturna, Zolgensma, Hemgenix and Roctavian, while manufacturing still struggles with yield, purity and scale. (mdpi.com; fda.gov) The same review described the production bottleneck in concrete terms: AAV therapies need large numbers of viral particles, but upstream cell culture, downstream purification and batch-to-batch consistency remain hard to control at commercial scale. (mdpi.com) That measurement problem is pushing attention toward analytics that look at cells one by one instead of averaging an entire tank. Flow cytometry does that by passing individual cells through lasers and reading light scatter and fluorescent signals in real time. (mdpi.com) A 2025 *BioTech* paper applied automated real-time flow cytometry to an *Escherichia coli* fed-batch process and reported continuous, operator-independent sampling that tracked single-cell behavior during L-phenylalanine production. (mdpi.com) The study used a triple-reporter strain in a scale-down bioreactor, a lab setup built to mimic the uneven conditions cells face in larger industrial vessels. The authors said those spatial heterogeneities can split one culture into subpopulations with different performance. (mdpi.com) That same logic applies to viral vector manufacturing, where a reactor may look uniform on paper while individual cells produce different amounts of capsid, genome-filled particles or stress signals. The *Viruses* review said process development now depends on better control of both vector design and manufacturing quality attributes. (mdpi.com) Clinical use has also sharpened the need for tighter monitoring because AAV is not frictionless medicine. FDA labels for Roctavian, Hemgenix, Luxturna and Zolgensma show the platform can treat severe inherited disease, but they also reflect product-specific limits tied to antibodies, liver monitoring, age or retinal viability. (fda.gov; fda.gov; fda.gov; fda.gov) Recent reviews have kept returning to the same constraint: immune responses can blunt efficacy, complicate re-dosing and add safety risk, which makes cleaner characterization of vector lots and host responses more important before and after infusion. (mdpi.com; mdpi.com) The thread connecting both papers is simple: gene therapy manufacturing is moving toward finer-grained surveillance, where watching single cells in motion may become as important as counting finished vials. (mdpi.com; mdpi.com)
